Guangdi Wang is a Professor of Chemistry in the Department of
Chemistry, Xavier University of Louisiana. Wang obtained his PhD in Chemistry
from the University of New Orleans in 1995 and joined Xavier University as a
faculty in the same year. Guangdi Wang’s research has focused on the discovery
of therapeutic targets by means of global proteomic analysis of diseased vs
normal biospecimen and the development of small-molecule drugs for cancer
treatment. His laboratory has designed, synthesized, and tested over three
hundred novel chemical entities as selective estrogen receptor modulators
(SERM) for breast cancer, anti-metastasis and vascular disrupting agents for
solid tumor treatment. Several lead compounds are in various stages of pre-clinical studies. He is the Principal Investigator and Program Director of Xavier’s RCMI Cancer Research Center
funded by NIH for the period of 2009 to 2019 with a total fund of over $20
million. Wang was the 2013 recipient of the Norman C. Francis Excellence in
Research award for a senior faculty at Xavier University.
Research Keywords & Expertise
Design, synthesis, and...
Novel lead compounds o...
Novel lead compounds o...
SERMs that are not cro...
SERDs that are not cro...
SERM/SERD hybrid
Reviews and perspectiv...
Fingerprints
23%
Design, synthesis, and biological evaluation of SERMs and SERDs
Short Biography
Guangdi Wang is a Professor of Chemistry in the Department of
Chemistry, Xavier University of Louisiana. Wang obtained his PhD in Chemistry
from the University of New Orleans in 1995 and joined Xavier University as a
faculty in the same year. Guangdi Wang’s research has focused on the discovery
of therapeutic targets by means of global proteomic analysis of diseased vs
normal biospecimen and the development of small-molecule drugs for cancer
treatment. His laboratory has designed, synthesized, and tested over three
hundred novel chemical entities as selective estrogen receptor modulators
(SERM) for breast cancer, anti-metastasis and vascular disrupting agents for
solid tumor treatment. Several lead compounds are in various stages of pre-clinical studies. He is the Principal Investigator and Program Director of Xavier’s RCMI Cancer Research Center
funded by NIH for the period of 2009 to 2019 with a total fund of over $20
million. Wang was the 2013 recipient of the Norman C. Francis Excellence in
Research award for a senior faculty at Xavier University.